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Introduction
The last decade has been witness to a radical 
change in the management of HIV disease. The first 
generation of antiretroviral drugs was burdened by a 
high degree of toxicity. The recent introduction of new 
molecules, characterized by high efficiency and im-
proved safety profiles, has not reduced the incidence 
of long-term adverse effects, in some cases manifested 
as selective organ damage, but in most cases as a 
systemic premature aging that seems to characterize 
HIV-positive patients1-3. This phenomenon is also known 
to occur in other chronic inflammatory diseases4.
Therefore, the presence of organ damage in patients 
receiving antiretroviral treatment is not only the expres-
sion of treatment toxicity, but also a complex interaction 
between individual risk factors, HIV-correlated effects, 
and antiretroviral drug toxicity. These long-term adverse 
events are currently defined as “non-infectious HIV-
related comorbidities”.
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Kidney damage belongs to these adverse events. 
Renal function abnormalities are present in a large 
percentage of patients with HIV infection. HIV-associ-
ated renal disease has become a relatively frequent 
cause of end-stage renal disease (ESRD) requiring 
dialysis and seems to be associated with progression 
to AIDS and death. In this review we address the mul-
tifaceted aspects of the epidemiology of renal damage, 
the complex interaction and the convergent effect of HIV 
and antiretroviral drugs in the onset of kidney injury, 
the interplay between kidney function and other organ 
systems, early clinical management, the possibility of 
a more thorough monitoring of renal function, and a 
proposed clinical approach to kidney disease in daily 
practice. Last but not least, we discuss future perspec-
tives of the renal damage in HIV patients, and we 
evaluate an important but frequently unrecognized issue: 
the patient’s perspective.
Epidemiology
Renal complications of HIV infection are becoming a 
major cause of morbidity and mortality. A survey con-
ducted during the period 1995 through 1999 evidenced 
a decreasing proportion of cytomegalovirus disease 
(from 6.8 to 2.8%), wasting/cachexia (9.8 to 6.8%), and 
dementia/encephalopathy (6.3 to 3.9%), while septice-
mia/septic shock (from 9.2 to 13.4%), and diseases of 
the liver (4.9 to 11.6%), kidney (6.3 to 9.1%), and heart 
(4.2 to 6.9%) showed an increasing prevalence. The 
observed trends in the pre-1995 era confirmed a de-
crease in the incidence of non-tuberculous mycobacte-
riosis (7.1 to 3.1%) and Kaposi’s sarcoma (5.3 to 2.6%)5.
In 2003, the HERS study showed that laboratory renal 
abnormalities, together with clinical AIDS, HIV RNA, 
and CD4 cell count, were the main specific determinants 
of hospitalization rates6.
Data from the HOPS cohort showed that among 
6,945 HIV-infected patients followed for a median of 
39.2 months, death rates fell from 7.0 deaths/100 per-
son-years in 1996 to 1.3 deaths/100 person-years in 
2004 (p = 0.008 for trend). Deaths that included AIDS-
related causes decreased from 3.79/100 person-years 
in 1996 to 0.32/100 person-years in 2004 (p = 0.008). 
Proportional increases in deaths involving liver dis-
eases, bacteremia/sepsis, gastrointestinal diseases, 
non-AIDS malignancies, and renal diseases were also 
reported (p ≤ 0.001, 0.017, 0.006, < 0.001, and 0.037, 
respectively)7.
In more recent studies, renal disease emerged as 
one of the leading causes of mortality among HIV-
positive patients: in 2009, data from the EuroSIDA 
cohort showed that after malignancies, cardiovascular 
diseases, and liver diseases, it was the fourth cause 
of death for non-AIDS-related diseases1. Data from 
EuroSIDA cohort study presented in 2010, including 
6,843 patients with at least three serum creatinine mea-
surements and corresponding body weight measure-
ments from 2004 onwards, evidenced that 225/6,843 
(3.3%) progressed to chronic kidney disease (CKD) 
during 21.482 person-years follow-up, giving an overall 
incidence of 1.05/100 person-years follow-up8.
Recent data from the Aquitaine cohort showed that the 
incidence rate of chronic renal failure was 1.27 cases 
per 100 person-years. It increased slightly over time: 
1.9% at one year, 3.3% at two years, 4% at three years, 
and 4.4% at four years. Factors associated with higher 
incidence were female gender, older age, diabetes, 
hyperlipidemia, low CD4 lymphocyte count, and expo-
sure to tenofovir9.
A study conducted on an urban U.S. HIV population 
found evidence of CKD in 24% of the patients. Forty 
patients (10%) had CKD stage 1, 19 patients (4%) 
stage 2, 29 patients (7%) stage 3, four patients (1%) 
stage 4, and eight patients (2%) stage 5. Patients with 
CKD were more likely to be African American, older, and 
have AIDS, lower CD4 counts, and higher HIV viral 
loads. Chronic kidney disease was also commonly 
associated to hypertension, diabetes mellitus, or both. 
Indinavir or tenofovir exposure was also associated 
with CKD. In multivariate analysis, hypertension, African 
American race, or hypertension and diabetes were 
the only significant predictors of CKD. Renal biopsies 
were done in 10 patients; five had HIV-associated 
nephropathy10.
On the other hand, laboratory renal alterations are 
frequent among HIV-positive patients: in a study enrolling 
2,057 HIV-positive women, 32% (n = 671) had protei-
nuria by dipstick on initial evaluation. Predictors of 
proteinuria included increasing (log) HIV RNA level 
(OR: 1.05), black race (OR: 2.0), absolute CD4 lympho-
cytes count ≤ 200 cells/mm3 (OR: 1.41), and the pres-
ence of hepatitis C antibody (OR: 1.27; all p < 0.0001). 
Absolute CD4 lymphocyte count ≤ 200 cells/mm3 (HR: 
3.57; p = 0.001), detectable HIV RNA level (HR: 2.33; 
p = 0.02), increased systolic blood pressure (HR: 1.02; 
p = 0.002), decreased albumin (HR: 3.33; p = 0.0001), 
and increased serum creatinine (HR: 1.67; p = 0.0001) 
were all associated with the development of renal failure. 
Finally, higher HIV RNA level and lower CD4 lympho-
cyte count correlated with the presence of proteinuria 
and occurrence of renal failure11.
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In another study conducted on 845 HIV-infected per-
sons, 30% of the patients had proteinuria and 43% had 
estimated glomerular filtration rate (eGFR) < 90 ml/
min/1.73 m2. Persons on HAART (63%) had a lower 
mean eGFR compared with naive patients (92.0 vs. 
101.6). In multivariate analyses, significant predictors 
of eGFR decline were diagnoses of hypertension, hy-
perlipidemia, proteinuria, use of tenofovir or stavudine, 
and lower viral load. The conclusions of the authors 
were that despite a low prevalence of chronic renal 
failure among HIV-infected outpatients, there was a 
high prevalence of asymptomatic renal dysfunction 
that was significantly greater than that of a well-matched 
control population12.
The association between age and increasing preva-
lence of CKD has relevant implications for the HIV-
infected population owing to the progressive ageing 
of this patient population. In fact, over a short period of 
three years between 2001 and 2004, the percentage 
of all HIV cases in patients aged ≥ 50 years increased 
from 17 to 23%13. This trend is expected to continue 
over the next decade. The increasing prevalence of 
HIV in older patients is a result of longevity in patients 
treated with HAART as well as new primary infections 
in more advanced age. The toxicities associated with 
HAART may be worse in older HIV patients, particularly 
those with underlying renal or hepatic insufficiency. 
Comorbidities are more common in older than in 
younger patients and can impact on the management 
of HIV in the former.
In a recent Italian study, the incidence and predic-
tors of a > 20% reduction in eGFR levels, or a decrease 
from ≥ 90 to < 90 ml/min/1.73 m2 from pre-combination 
antiretroviral therapy were evaluated in a total of 
1,505 patients; 24% had eGFR < 90 ml/min/1.73 m2 at 
baseline. Age, female gender, diabetes, hypertension, 
and higher baseline CD4 count were all associated 
with a greater risk of eGFR < 90 ml/min/1.73 m2. Ninety-
six patients experienced a decrease in eGFR of > 20% 
from pre-combination antiretroviral therapy levels 
(6.8/100 person-years). Besides the general factors, 
current exposure to didanosine, tenofovir, and pro-
tease inhibitors (PI) were the major determinants14.
Acute renal failure occurs commonly among hos-
pitalized patients with HIV and is associated with 
CKD, liver disease, and increased mortality: among 
52,580 HIV-infected patients discharged from hospital 
in 1995 and 25,114 in 2003, compared with uninfected 
patients, HIV-infected patients had an increased inci-
dence of acute renal failure in both the pre-HAART and 
post-HAART eras. In the post-HAART cohort, acute 
renal failure was associated with traditional predictors 
such as age, diabetes mellitus, and CKD, as well as 
acute or chronic liver failure or hepatitis coinfection. 
Acute renal failure was associated with mortality among 
HIV-infected patients in the post-HAART era15.
HIV-associated nephropathy (HIVAN) has massively 
influenced the epidemiology in the USA and, until now, 
only marginally Europe, although migratory flows could 
determine in the future an increase in the number of 
cases. In fact, over 85% of cases of HIVAN occur in 
African American patients and it represents the third 
leading cause of ESRD in blacks aged 20-6416.
African Americans seem to have a more aggressive 
natural disease history. In a cohort in Baltimore, 
Maryland, the authors measured CKD incidence, GFR 
slope, and progression to ESRD in 3,332 African 
American and 927 white HIV-infected subjects. A total 
of 284 subjects developed CKD, 35% of whom subse-
quently developed ESRD. African American subjects 
were at slightly increased risk for incident CKD com-
pared with white subjects. However, once CKD has 
been established, the African American subjects de-
veloped ESRD markedly faster than white subjects 
and, correspondingly, their GFR decline after diagno-
sis of CKD was sixfold more rapid. In the subset of 
African American subjects for whom kidney biopsy 
data were available, progression to ESRD was signifi-
cantly faster, irrespective of the presence of HIVAN17.
HIV infection and renal involvement
HIV infection may promote renal diseases. However, 
in the last years, due to the widespread employment 
of HAART, there has been a decline in renal involve-
ment as a consequence of viral infection.
As seen above, HIVAN, the typical expression of 
HIV-related renal disease, is still a major concern, but 
is practically confined to the black population. The 
potential evolution towards ESRD has been significantly 
hampered by HAART18 and, differently from the pre-
HAART era, survival of patients requiring renal replace-
ment therapy, including renal transplantation, is similar 
to that of non-HIV subjects. Typically, HIVAN is char-
acterized by massive proteinuria that, generally speak-
ing, is a major diagnostic and prognostic factor of renal 
involvement. In fact, this is a marker of renal inflamma-
tion and, at the same time, a prognostic indicator of 
increased cardiovascular risk19. Besides this specific 
disease, HIV patients may experience an acute dete-
rioration of renal function, or acute kidney injury (AKI), 
for which the RIFLE20 or AKIN21 criteria have catego-
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rized different clinical situations with a variable out-
come. Major contributors to AKI typically include sep-
sis, viral load, and concomitant HBV- or HCV-related 
diseases, but a growing role is played by nephrotoxins 
and HAART22. Microangiopathic factors contribute to 
acute and chronic kidney damage. Immune complex 
glomerulonephritides, such as IgA nephropathy or 
other forms, are common, especially in Caucasian pa-
tients. Selective tubular damage with clinical pictures 
of Fanconi’s syndrome, nephrogenic diabetes insipi-
dus, or renal tubular acidosis is also associated to 
toxicity of some antiretrovirals such as indinavir, cido-
fovir, and most recently tenofovir. A summary of the 
spectrum of renal involvement in HIV is reported in 
table 1.
HIVAN, defined by renal biopsy or clinical criteria, 
occurs in less than 1-12% of black patients23. It is 
characterized by a clinical appearance of nephrotic 
proteinuria, increased echogenicity of kidneys, lack of 
hypertension or relevant edema, and progressive renal 
failure. Histological examination of the renal biopsy 
specimen shows focal and segmental glomerulosclero-
sis, often the collapsing variant. A direct pathogenetic 
role of HIV has been ascertained; however, given the 
almost exclusive involvement of descendants from 
African ancestors, a genetic predisposition has been 
advocated and specific gene loci invoked, like the 
MYH9 locus on chromosome 2224. The more rapid 
evolution toward ESRD seems to be dependent on the 
extent of the renal damage as ascertained by histological 
examination of renal biopsy and not the time of initiation 
of HAART23.
A spectrum of other glomerulonephritides and renal 
diseases has been reported in HIV patients. Some of 
them, like immune complex glomerulonephritis, IgA 
nephropathy, or thrombotic microangiopathy, are 
strictly linked to the viral infection. For some other 
forms, like post-infectious glomerulonephritis, lupus-like 
nephritis or immunotactoid glomerulopathy, the asso-
ciation is less direct and needs to be sought in each 
individual case. Finally, the occurrence of interstitial 
nephritis or membranous nephropathy is unlikely linked 
pathogenetically to the HIV infection and may be just 
a concomitant association25.
Microalbuminuria has been advocated as a risk factor 
for cardiovascular diseases (CVD) in diabetics, but its 
role in hypertensive nondiabetic patients is less clear. 
Studies conducted in HIV-infected individuals have 
shown that 9-20% of subjects present microalbuminu-
ria and this prevalence is 2-5 times higher than in the 
control population26-28. In general, microalbuminuria 
correlated with HIV-dependent factors or HAART, such 
as the longevity of infection or lower CD4 count, may 
be more frequent in patients taking nonnucleoside re-
verse transcriptase inhibitors (NNRTI) and may be 
linked to an immune activation state induced by the 
viral load, as documented by increased mean levels of 
β2-microglobulin26. The HIV patients that present mi-
croalbuminuria are at increased risk to develop overt 
proteinuria27. However, as in the general population, 
Table 1. Predominant renal involvement in HIV-infected patients
Class of nephropathy Specific disease Pathogenetic and histologic aspects
Glomerular diseases HIVAN Focal and segmental glomerulosclerosis, “collapsing variant”
Immune complex GN Mesangial proliferative GN with IgA immune deposits  
(secondary IgA nephropathy) or diffuse proliferative GN with IgG, 
IgM, C3 and C1q immune deposits (Lupus-like proliferative GN) 
Other GN Membranous GN or membranoproliferative GN, immunotactoid GN
Vascular nephropathy Hemolytic-uremic 
syndrome
Microangiopathy, hyaline glomerular thrombi, necrosis, swollen 
glomerular endothelium 
Tubulointerstitial 
nephritis
Acute or chronic TIN Hypersensitivity reactions to drugs: tubulitis, marked interstitial 
leukocyte infiltration, fibrosis, tubular atrophy
Drug toxicity: tubular atrophy, Fanconi’s syndrome
Acute kidney injury Acute drug (antiretroviral 
or antibiotics) toxicity, 
sepsis,
rhabdomyolysis
Toxic acute tubular necrosis 
HIVAN: HIV-associated nephropathy; GN: glomerular neuropathy; TIN: tubulointerstitial nephritis.
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microalbuminuria is also significantly linked to cardiovas-
cular risk factors such as hypertension, diabetes, or in-
sulin resistance28. In summary, an increased prevalence 
of microalbuminuria occurs in HIV patients, probably 
triggered by the infection itself, and its epidemiological 
meaning carries all the potential of a predictor of CVD.
Acute kidney injury is very frequent in hospitalized 
HIV patients and, as reported before, the increased risk 
compared to noninfected patients has not been changed 
by the introduction of HAART29. Eighteen percent of hos-
pitalized HIV patients experience AKI as a complication, 
which determines a significant morbidity and mortality. 
Common risk factors for developing AKI are ethnicity 
(blacks more susceptible), other general and specific 
comorbidities (low CD4 count, longer exposure to HAART, 
and HCV coinfection)30 and previous CKD. The most 
relevant aspect is that AKI is associated with an increased 
incidence of CVD, heart failure, ESRD, or death, espe-
cially in those patients which experience a severe renal 
complication requiring dialytic support31. The initiation of 
HIV care in specialized clinics significantly reduces the 
incidence of AKI episodes in ambulatory patients32.
Chronic kidney disease, defined as eGFR < 60 ml/
min/1.73 m2, occurs more commonly in patients with 
an HIV-induced immune activation, adverse metabolic 
consequences of HAART and/or renal toxicity of HAART 
and is much more common in advanced immunodefi-
ciency. In large cohorts, 2.4-10% of patients devel-
oped CKD; predictive factors were older age, lower 
CD4 count at nadir, and an AIDS-associated condition. 
While most of the black patients experienced CKD as 
a progression of HIVAN, in white subjects relevant fac-
tors were exposure to nephrotoxic drugs such as indi-
navir or tenofovir, besides a range of common co-
mordibities10,12,33,34. On the other hand, in African HIV 
patients with advanced diseases and mild renal dys-
function, the introduction of HAART produced a sig-
nificant overall improvement of renal function by about 
20% after two years of treatment35. However, some 
drugs used in the HAART regimen (tenofovir associ-
ated with PI) may favor a more rapid decline of renal 
function compared to other therapeutic protocols (ten-
ofovir and NNRTI)36.
End-stage renal disease occurs as a progression of 
CKD. The rate of progression is faster in African Ameri-
can than white patients37. Mathematical models have 
estimated a reduction of 38% of the evolution from 
AIDS to ESRD after the introduction of HAART in the 
mid-1990s38; however, the absolute number of HIV 
patients requiring dialysis should linearly increase up 
to 2020, due to an increase in HIV infection among 
black patients39. Survival of HIV patients requiring he-
modialysis seems to be worse than that of noninfected 
patients40,41, although a French national survey at the 
beginning of the new century has reported an equal 
survival rate after a two-year follow-up42.
Kidney and other organs
In this section we will analyze the implications of 
kidney function over other organ systems. These impli-
cations can be relevant in a context such as that of HIV 
infection because of the linkage between the role of 
the virus, the general health status of the patient, and 
the toxicity of drugs.
The kidney is involved in many processes related to 
the vitamin D cycle, bone metabolism, and CVD.
Remarkably, the renal 1α-hydroxilation of 25-hydroxy-
cholecalciferol (25[OH]D) leads to the final activation 
of vitamin D into calcitriol, the so-called hormone D. As 
known, vitamin D regulates phosphate metabolism 
both by favoring its gastrointestinal absorption and 
accumulation in bone, but it also decreases renal excre-
tion. As a consequence, vitamin D deficiency results in 
insufficient bone mineralization and then osteomalacia.
Together with proximal tubular reabsorption of phos-
phate, the kidney also controls the reabsorption of 
calcium in the distal tubule; thus it is clear that renal 
dysfunction can contribute to a disruption in bone 
homeostasis.
The picture worsens further owing to the direct action 
of HIV on bone cells that is exerted both by an en-
hancement of osteoclastogenesis and by inhibition of 
osteoblast differentiation and biological activity44.
Numerous and updated literature confirms these no-
tions in HIV-1-infected people: Dao, et al. found that 
71.6% of HIV-1-infected patients followed in a prospec-
tive observational cohort had insufficient levels of 
25(OH)-vitamin D and this value correlated significant-
ly with renal insufficiency (eGFR < 90 ml/min/1.73 m2) 
and ritonavir exposure45.
In a large HIV-infected patient cohort, the prevalence 
of insufficiency of vitamin D (< 75 nmol/l) was found in 
54% of subjects, whereas deficiency was found in 7%. 
Race and duration of antiretroviral therapy were inde-
pendent factors associated with the risk of insufficien-
cy of vitamin D, although the prevalence of a specific 
antiretroviral class was not demonstrated46.
A recent French cohort study has found that 90% of 
treated patients had vitamin D deficiency (< 15 ng/ml) 
and suggested a specific role of HAART as a causative 
factor47.
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In a retrospective study on bone mineral density 
(BMD) of HIV-1-infected patients, measured by dual-
energy X ray absorptiometry (DEXA), a progression 
over time to osteopenia and osteoporosis was found. 
Some of the factors related to low BMD were similar to 
those described in the general population (age, sex, 
low body mass index), but others were related to HIV-
specific conditions: antiretroviral therapy and specifi-
cally PI and tenofovir use48.
Patients treated with tenofovir showing laboratory 
signs of renal proximal tubular dysfunction were char-
acterized by an imbalance in bone turnover (10% of 
patients presented osteoblast activation and 51% high 
bone resorption) that was correlated with lower eGFR, 
vitamin D deficiency, and hyperparathyroidism49.
The association between tenofovir use and second-
ary hyperparathyroidism was also shown in a recent 
study by Pocaterra, et al. Even though the influence of 
the high prevalence of hypovitaminosis D on parathyroid 
hormone through calcium serum levels was evident, an 
independent effect of tenofovir use also emerged50.
Regarding the correlation between renal impairment 
and CVD, a very large meta-analysis has shown that 
eGFR ≤ 60 ml/min/1.73 m2 and albumin/creatinine ratio 
≥ 1.1 mg/mmol were independent predictors of all 
causes and cardiovascular mortality risk in the general 
population51.
In HIV-1-infected populations, similar conclusions 
have been drawn. A recent national longitudinal study 
has confirmed the association between kidney function 
and albumin excretion with the occurrence of athero-
sclerotic CVD and/or heart failure, adding that kidney 
function and albuminuria provide complementary prog-
nostic information that may facilitate CVD risk stratifica-
tion in HIV-infected persons19.
In a case-control study, patients who had cardio-
vascular events (n = 63) were compared with controls 
(n = 252) matched by eGFR and proteinuria: an inde-
pendent association between decreased kidney func-
tion and increased risk of cardiovascular events in 
HIV-1-infected people was demonstrated, in addition 
to more traditional risk factors such as history of car-
diovascular events, diabetes mellitus, dyslipidemia, 
and low CD4+ count52.
In patients of the Veterans Administration Cohort, 
when screened for myocardial infarction and cerebro-
vascular events, CKD was found to be correlated with 
an increased risk of myocardial infarction (HR: 3.85; 95% 
CI: 2.74-5.42; p < 0.0001 for eGFR < 60 ml/min/1.73 m2; 
HR: 1.33; 95% CI: 1.00-1.76; p = 0.048 for eGFR 60-89 
ml/min/1.73 m2)53.
In summary, kidney function is an important regulator 
of bone homeostasis and is considered a cofactor in 
the occurrence of CVD, both in general and in HIV-1-
infected populations. Monitoring renal function pa-
rameters is an important component of the overall 
treatment of HIV-1 infection.
Antiretroviral drugs and renal toxicity
The global effects of HAART on renal function and 
the incidence of chronic renal disease among HIV-in-
fected patients are debated still today.
Positive effects of HAART on kidney function have 
been demonstrated in several cohort studies. In fact, 
the introduction of new antiretroviral regimens and the 
persistent viral suppression correlated with a declining 
incidence of CKD and a significant improvement in 
eGFR54-57. However, HAART itself can cause renal 
toxic effects, and prolonged used of antiretroviral 
drugs in HIV-infected patients may lead to the develop-
ment of kidney dysfunction by several pathogenetic 
mechanisms58-61.
The following paragraphs describe the rates and 
mechanisms of common toxic renal effects associated 
with different classes of antiretroviral agents.
Protease inhibitors
Indinavir is the protease inhibitor (PI) that has been 
most commonly associated with renal toxic effects, 
including nephrolithiasis, intratubular drug deposition, 
crystalluria, dysuria, hematuria, renal colic, papillary 
necrosis, renal atrophy, acute interstitial nephritis, and 
acute and chronic renal failure62,63. Symptoms may 
occur as early as one week following initiation of indi-
navir therapy and urinary crystals composed of indina-
vir may form in any structure of the kidney and the 
urinary tract. Crystalluria was reported in about 20% of 
all patients treated with this PI, and this condition pro-
gressed to nephrolithiasis in 3% of all subjects64.
Retrospective and prospective studies demonstrated 
that the incidence of urological complications among 
indinavir-treated patients was about 8-10 cases per 
100 treatment-years, and risk factors for the develop-
ment of nephrolithiasis were urine pH > 6, low lean 
body mass level, inadequate hydration, high plasma 
levels of indinavir, chronic hepatitis B or C, and con-
comitant therapy with low-dose ritonavir or other 
nephrotoxic drugs65-68. Most urologic symptoms and 
elevations in serum creatinine usually normalize within 
weeks after the discontinuation of indinavir, although 
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irreversible renal toxicity and chronic renal failure were 
described62,63.
Several case reports of nephrolithiasis and AKI were 
also reported in association with full-dose ritonavir, 
saquinavir, nelfinavir, and lopinavir/ritonavir therapy, 
but the etiology of renal damage remains unclear69-72. 
Observations of urolithiasis in saquinavir-treated pa-
tients are exceptional, and no renal toxicity has been 
attributed to saquinavir in controlled trials73.
Atazanavir has not been associated with urolithiasis 
or crystalluria in clinical studies, but several cases of 
nephrolithiasis and interstitial nephritis were reported 
in atazanavir-treated patients.
In a retrospective study including 1,134 patients who 
were receiving ritonavir-boosted atazanavir from 2004 
through 2007, only 11 cases of atazanavir-associated 
nephrolithiasis were diagnosed, and all cases occurred 
within two years after starting atazanavir treatment. 
Patients with low water intake, high urinary pH, and a 
prior history of urinary stones may have a greater risk 
of urine crystallization74. Similarly, 30 cases of ataza-
navir-induced nephrolithiasis were recorded over a 
four-year study period in the Adverse Event Reporting 
System Database75, but no cases of CKD were ob-
served in these series. The mechanism of developing 
renal stones is unknown, but is probably linked to uri-
nary precipitation of atazanavir, as has been described 
for indinavir stones. Finally, isolated cases of interstitial 
nephritis with acute renal failure were described in as-
sociation with atazanavir or atazanavir/tenofovir thera-
py, but withdrawal of antiretroviral treatment resulted 
in recovery of renal function76.
Thus, to date, the incidence of atazanavir-induced 
nephrolithiasis and interstitial nephritis appears to be 
very low, given that atazanavir has been administered 
to a very high number of patients worldwide.
Cases of nephrolithiasis were reported during post-
marketing surveillance in HIV-infected patients receiv-
ing fosamprenavir. Because these events were report-
ed voluntarily during clinical practice, estimates of 
frequency cannot be made. If signs or symptoms of 
nephrolithiasis occur, temporary interruption or discon-
tinuation of therapy may be considered77.
Nonnucleoside reverse transcriptase 
inhibitors
Data concerning kidney toxicity from NNRTI are very 
limited because nevirapine, efavirenz, and etravirine 
have usually demonstrated a safe renal profile in con-
trolled clinical trials.
A small number of cases of crystalluria or obstructive 
uropathy associated with the administration of efa-
virenz have been reported78,79. Moreover, a single case 
report linked efavirenz to a hypersensitivity reaction 
including interstitial nephritis and acute renal failure. 
Prompt discontinuation of antiretroviral treatment and 
use of corticosteroids resulted in rapid recovery of 
renal function80.
Nucleoside reverse transcriptase inhibitors
Renal toxicity associated with the use of nucleoside 
reverse transcriptase inhibitors (NRTI) is generally 
uncommon in clinical trials, but several episodes of 
nephrotoxicity and tubular dysfunction have been re-
ported in subjects treated with nucleoside analogues.
Animal studies have shown that metabolic abnor-
malities, such as hypokalemia and hypomagnesemia, 
may predispose to NRTI-induced nephrotoxicity81-84.
Mitochondrial toxicity may be induced by NRTI-
based therapy, particularly with stavudine, didanosine, 
or zidovudine. Asymptomatic hyperlactatemia following 
mitochondrial damage occurs in 20-30% of HIV-infect-
ed patients receiving NRTI, and may infrequently lead 
to severe lactic acidosis and acute renal failure85. An-
other report described acute interstitial nephritis with 
renal failure in association with a hypersensitivity reac-
tion to abacavir: renal function had improved by two 
weeks after abacavir withdrawal86.
Tenofovir
Apart from a small number of case reports of neph-
rotoxicity associated with PI-, efavirenz-, or NRTI-based 
therapy, concern over antiretroviral drug-induced renal 
toxicity has been largely focused on tenofovir.
The literature about tenofovir use and renal disease 
is non-standardized, without diagnostic specificity for 
the cause of renal abnormalities, and retrospective and 
prospective studies often produce confusion about the 
true incidence or prevalence of this complication. In 
the selected populations enrolled in clinical trials with 
rigorous monitoring of renal function, tenofovir appears 
to be associated with a low risk of nephrotoxicity and 
this adverse event occurs mostly in patients with pre-
disposing kidney disease or comorbidities87-90.
However, several case reports and various observa-
tional studies have found evidence of potential renal 
toxicity induced by tenofovir treatment, mostly including 
proximal tubulopathy with Fanconi’s syndrome and 
nephrogenic diabetes insipidus. Tenofovir is the 
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antiretroviral agent most commonly associated with 
Fanconi’s syndrome, which can potentially lead to calci-
um and phosphorus dysregulation, acute renal failure, 
osteomalacia, and fractures. Moreover, analyses of large 
datasets from tenofovir clinical trials have shown that 
a mild decrease in GFR may sporadically occur58-61.
Tenofovir is excreted by the kidney via a combination 
of glomerular filtration and active tubular secretion. On 
the basolateral side of the proximal tubular cell, teno-
fovir influx occurs primarily through the human organic 
anion transporter (hOAT)-1, while multidrug resistance 
protein (MRP)-2 and -4 are responsible for its cellular 
efflux61,91 (Fig. 1).
A retrospective review of the Food and Drug Admin-
istration Adverse Events Reporting System from 2001 
through 2006 registered 164 subjects who met the 
case definition for Fanconi’s syndrome. The majority of 
these subjects (83%) received tenofovir with PI, while 
didanosine was the most frequently (43%) prescribed 
NRTI92. Similarly, in a retrospective cohort analysis of 
1,647 patients enrolled in the Kaiser Permanente Health 
Maintenance Organization during 2002 to 2005, tenofovir 
exposure was found to be significantly associated with 
a decline in GFR and proximal tubular dysfunction93.
A cross-sectional study involving 845 HIV-infected 
outpatients showed a prevalence of chronic renal failure 
higher than that of the general population, and significant 
predictors of lower GFR in multivariate analyses were 
found to be use of tenofovir or stavudine12.
In the ANRS CO3 Aquitaine Cohort, 2,613 HIV-infect-
ed patients were followed-up between 2004 and 2008 
to estimate the incidence of chronic renal failure and 
related risk factors. The incidence rate of chronic renal 
failure was much higher (12.7 cases for 1,000 persons-
years) than that observed in the general population of 
similar age, and factors associated with higher incidence 
included immunodeficiency and tenofovir exposure94.
Some other prospective cohort studies have empha-
sized similar results. The Swiss HIV Cohort Study found 
a consistent evidence for a significant reduction in GFR 
associated with tenofovir use95. In the HIV Outpatient 
Study (HOPS), use of tenofovir-containing HAART was 
associated with modest decreases in GFR during the 
first year of therapy, but clinically significant renal tox-
icity was very uncommon96, and decline in GFR in 
subjects with preexisting renal dysfunction was also 
very limited97.
The incidence of CKD was investigated in the Euro-
SIDA Cohort Study, including 6,843 HIV-infected per-
sons followed-up from 2004 onwards. Progression to 
chronic nephropathy was observed in 225 patients 
(3.3%) during 21,482 person-years follow-up, with an 
incidence of 1.05/100 person-years follow-up. After 
adjustment for traditional risk factors, exposure to ten-
ofovir was significantly associated with a higher inci-
dence of CKD, as was true for indinavir and atazanavir, 
whereas the results for lopinavir/ritonavir were less 
evident8.
The same research reveals that patients treated with 
tenofovir, who stopped the administration of the drug, 
continued to have a significant increased incidence of 
CKD during the first year after stopping, suggesting 
that the effect of the drug is not easily reversible.
Tenofovir-associated nephrotoxicity more frequently 
involves the tubular function, and more interesting data 
result from studies investigating clinical or subclinical 
renal tubular toxicity. However, it is unclear whether 
spot proteinuria, glycosuria or urine protein/creatinine 
or albumin/creatinine ratio are sufficiently sensitive 
screening tests to detect subclinical tubular dysfunc-
tion, and other markers should be considered (such as 
hyperaminoaciduria, hyperphosphaturia, or hyperuri-
cosuria), as we will see in the next section.
In a cross-sectional study including 99 HIV-infected 
patients with serum creatinine levels < 1.7 mg/dl and 
dipstick-negative proteinuria, subjects using tenofovir 
had increased urine retinol-binding protein/creatinine 
ratio and protein/creatinine ratio, showing a subclinical 
renal tubulopathy98. A cross-sectional study of plasma 
and 24-hour urine markers of tubulopathy (glycosuria, 
hyperaminoaciduria, hyperphosphaturia, hyperuricosu-
ria, and beta2-microglobulinuria) in 284 HIV-positive 
patients demonstrated a significant correlation between 
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hOAT: human organic anion transporter; 
MRP: multidrug resistance protein.
Figure 1. Proposed mechanism of active tubular secretion of tenofovir.
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exposure to tenofovir and tubular dysfunction in the 
absence of impaired glomerular function99. Similar find-
ings were found in the ASSERT study, a multicenter, 
randomized, open-label trial comparing the safety pro-
files of tenofovir/emtricitabine and abacavir/lamivudine 
in association with efavirenz in 385 HIV-infected sub-
jects. After a 48-week follow-up, no difference in eGFR 
was observed between the arms, but markers of tubu-
lar damage (urinary excretion of retinol-binding protein 
and beta2-microglobulin) increased significantly in the 
tenofovir/emtricitabine group100.
Predictors of kidney tubular dysfunction in patients 
treated with tenofovir were also investigated. Increased 
age, lower body weight, higher tenofovir plasma levels, 
and concomitant use of didanosine, amprenavir, or 
ritonavir-boosted PI were found to be associated with a 
higher risk of CKD in tenofovir-treated individuals36,95,101-103. 
Coadministration of tenofovir increases plasma concen-
tration of didanosine by 40-60%, possibly via pharma-
cokinetic competition for hOAT-1 in the proximal tubular 
cells, increasing the risk of nephrotoxic effects61.
Polymorphisms in genes associated with kidney cel-
lular transporters could explain different toxic effects 
of and therapeutic responses to antiretroviral drugs. A 
pharmacogenetic study assessing 115 HIV-infected 
patients receiving tenofovir-containing HAART showed 
an increased risk of kidney tubulopathy among those 
with genotype CC than among those with genotypes 
CT and TT at position –24 of ABCC2 gene encoding 
the cellular transporter MRP2104. Similarly, mutational 
screening of 30 HIV-positive patients has demonstrat-
ed a significant allelic association between the single-
nucleotide polymorphism G→A of the ABBC2 gene 
and tenofovir-induced proximal tubulopathy105.
On the contrary, results from clinical trials have 
shown no evidence of renal toxicity when tenofovir is 
used as part of an initial antiretroviral regimen106-108. 
Gallant, et al.109 evaluated 432 antiretroviral-naive pa-
tients who initiated either tenofovir or any alternative 
NRTI after January 2002. Patients taking both tenofovir 
and NRTI experienced an initial decline in GFR during 
the first six months of therapy, but renal function sta-
bilized between six and 24 months. By multivariate 
analysis, there was no difference between the tenofovir 
and NRTI groups in 25 or 50% decline in GFR, while 
subjects taking tenofovir and boosted PI had a greater 
median decline in GFR than those taking tenofovir and 
a NNRTI. However, in a previous report of the Johns 
Hopkins Cohort, use of tenofovir was found to be 
associated with a greater decline in renal function than 
use of alternative nucleoside analogues110.
In conclusion, although clinically evident nephrotoxicity 
induced by tenofovir occurs only sporadically, several 
data indicate a significant negative impact on the prox-
imal tubule, also in terms of progression of damage. 
Moreover, its potential long-term effects on kidney 
function are still unknown. Therefore, long-term monitor-
ing of renal function and markers of tubular dysfunction 
should be considered in patients taking tenofovir, par-
ticularly those with comorbidities (such as preexisting 
renal disease, hypertension, and diabetes) or predis-
posing factors (including increased age and current 
therapy with boosted PI or other nephrotoxic drugs).
Other antiretroviral drugs
In the safety analysis of the TORO-1 and TORO-2 
trials, including over 600 subjects treated with enfuvirtide, 
one patient with a previous history of proteinuria and 
hematuria exhibited a hypersensitivity reaction with a 
membranoproliferative glomerulonephritis111.
No evidence exists that fusion inhibitors (enfuvirtide), 
CCR5-receptor antagonists (maraviroc), or integrase 
inhibitors (raltegravir) have potential nephrotoxic effects. 
Although available data are still limited, these drugs 
have usually shown a good renal safety profile in clinical 
studies111-114. Further enlarged studies are requested 
in order to better investigate the potential nephrotoxic 
effects of new antiretroviral compounds.
Dose changes recommended in patients with renal 
insufficiency are summarized in table 2.
Markers
Glomerular function evaluation
Creatinine clearance measuring methods
Evaluation of serum creatinine is the most used 
marker in clinical practice in order to estimate renal 
function, but it is not an exact predictor of GFR as the 
levels of creatinine are influenced by several other 
factors such as muscular mass, age, sex, race, use of 
steroids, and diet. When considering methods, one 
can list accuracy and precision on one side and costs 
and feasibility on the other. Serum creatinine is obvi-
ously the simplest and most economical test, but is 
less precise and specific. At the opposite (maximum 
accuracy, less feasibility) there is the renal clearance 
of inulin or EDTA. Creatinine clearance measured on 
timely collected urine is an indirect assessment of GFR 
and is often affected by the imprecision in the collection 
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process. To overcome these difficulties, eGFR is a 
valid alternative, which needs only serum creatinine 
measurement and some anthropometric parameters. 
Both the modification of diet in renal disease (MDRD) 
and Cockroft-Gault formulas (placed between the two 
extremes of accuracy and simplicity) represent a good 
compromise in daily clinical practice for follow-up of 
the kidney function115-117. The recently introduced 
Table 2. Summary of dose reductions for antiretrovirals in patients with renal failure
Class Drug Recommended daily dosing in patients with renal insufficiency
NRTI Abacavir No adaptation; no data for end-stage renal disease
Didanosine Weight < 60 kg ≥ 60 kg
CrCl 30-59 ml/min: 125 mg 200 mg
CrCl 10-29 ml/min: 125 mg 125 mg
CrCl < 10 ml/min: 75 mg* 125 mg
HD, CAPD: 75 mg* 125 mg
Emtricitabine CrCl 30-49 ml/min: 200 mg/48 hours
CrCl 15-29 ml/min: 200 mg/72 hours
CrCl < 15 ml/min or HD: 200 mg/96 hours (take dose after HD session 
on dialysis days)
Lamivudine CrCl 30-49 ml/min: 150 mg/24 hours
CrCl 15-29 ml/min: 1 x 150 mg, then 100 mg/24 hours
CrCl 5-14 ml/min: 1 x 150 mg, then 50 mg/24 hours
CrCl < 5 ml/min or HD: 1 x 50 mg, then 25 mg/24 hours (take dose after 
HD session on dialysis days)
Stavudine Weight < 60 Kg ≥ 60 kg
CrCl 26-50 ml/min: 15 mg/12 hours 20 mg/12 hours
CrCl 10-25 ml/min or HD: 15 mg/24 hours 20 mg/24 hours (take dose 
after HD session on dialysis day)
CrCl < 10 ml/min (not on HD): no data
Tenofovir CrCl 30-49 ml/min: 300 mg/48 hours
CrCl 10-29 ml/min: 300 mg twice a week
CrCl < 10 ml/min not on HD: no data
HD: 300 mg once a week (take dose after HD session on dialysis day)
Zidovudine CrCl < 15 ml/min or HD: 100 mg/8 hours or 300 mg/24 hours
Emtricitabine + tenofovir 
(co-formulated)
CrCl 30-49 ml/min: 1 tablet/48 hours
CrCl < 30 ml/min: not recommended
NNRTI Efavirenz, etravirine, 
nevirapine
No adaptation
Protease inhibitors Darunavir CrCl ≥ 30 ml/min: no adaptation
CrCl < 30 ml/min: no data
Lopinavir, saquinavir No adaptation
Fosamprenavir, 
indinavir, nelfinavir
No data
Entry inhibitors Enfuvirtide No adaptation
Maraviroc CrCl < 80 ml/min: 
without a concomitant potent CYP3A inhibitor or inducer: no adaptation
with a concomitant potent CYP3A inhibitor or inducer: 150 mg/24 hours
with fosamprenavir: 150 mg/12 hours
Integrase inhibitors Raltegravir No adaptation
* Oral solution.
NRTI: nucleoside reverse transcriptase inhibitors; NNRTI: nonnucleoside reverse transcriptase inhibitors; CrCl: creatinine clearance; HD: hemodialysis; CAPD: continuous 
ambulatory peritoneal dialysis.
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CKD-EPI formula to assess eGFR has a better perfor-
mance than MDRD, especially in the near-normal renal 
function; however, in order to apply such a formula, 
serum creatinine levels need to be measured by a 
laboratory method that uses a reference-standardized 
creatinine calibrator, not readily available in all clinical 
chemistry laboratories118.
Cystatin C
Another marker of glomerular function is cystatin C, 
produced constantly by almost all the cells, filtered 
completely by the glomerulus and then reabsorbed 
and catabolized by renal tubules. A study on HIV-
related kidney diseases evidenced that serum cystatin 
C was higher in 1,008 HIV-positive patients than in 
HIV-negative subjects, even if all subjects showed 
similar values of serum creatinine119.
Serum cystatin C concentrations are affected by 
several factors such as sex, age, and race; but, differ-
ently from creatinine, it does not seem to be influenced 
by muscle mass120. The persistent inflammatory state 
seen in HIV-infected patients may contribute to increase 
mean levels of cystatin C in these patients121. This is 
another confounding factor limiting its use as GFR 
marker in this particular group of patients.
Evaluation of tubular function
Serum/urine phosphorus concentration
HIV-infected patients seem to have additional causes 
of low serum phosphorus concentration compared with 
the general population122, such as:
− Hypovitaminosis D: in literature there is a great 
evidence of this condition related to HIV status. 
Several factors have accounted for this such as 
the in vitro demonstrated effect of reduction of the 
25- and 1- hydroxylation by protease inhibitors123; 
in literature a role of efavirenz has been proposed 
as well124. The hypovitaminosis D has been re-
cently described as cofactor in the reduced bone 
mineralization in HIV-infected patients125.
− Toxicity on proximal tubule by HAART or HIV itself.
Monitoring of phosphorus metabolism is mandatory 
in this group of patients; besides vitamin D, other factors 
that need surveillance are parathyroid hormone and 
bone alkaline phosphatase. Moderate increased levels 
of parathyroid hormone are associated with vitamin D 
insufficiency or deficiency. Probably, an early event is 
represented by the increased urinary phosphate excretion 
that needs an accurate evaluation, better if correlated 
to GFR (TmPO4/GFR) according to the nomogram of 
Walton and Bijvoet126.
Proteinuria, uricosuria, and glycosuria
These are all markers of tubular damage127. In the 
study of Hall, et al., several markers of subclinical 
damage were analyzed; however, it remains unclear if 
spot urines are reliable specimens in order to estimate 
subclinical tubular damage. Generally, the examination 
of 24-hour collected urine is required98. In the guide-
lines for the screening of CKD in HIV of the National 
Kidney Foundation128, several methods of measurement 
of proteinuria are compared: dipstick (semiquantitative 
method); proteinuria on spot urines (quantitative), 
preferentially collected in the morning, with calculation 
of urinary protein/creatinine and albumin/creatinine ratios; 
proteinuria in 24-hour collected urines (gold standard, 
but potentially influenced by mistakes in collection and 
consequent under/overestimation).
The Infectious Diseases Society of America (IDSA) 
guidelines suggest the use of dipstick for the estimate 
of proteinuria116. Such method has a sensitivity of 
approximately 60% and a positive result must be 
confirmed measuring the protein/creatinine ratio or 
albumin/creatinine ratio on randomly sampled urine 
(better if collected in the morning).
It is important to calculate both total urinary protein 
and albumin ratios in order to discriminate between 
glomerular proteinuria and tubular proteinuria129. In 
some clinical conditions, no direct correlation exists 
between 24-hour proteinuria and protein/creatinine 
ratio on spot urine samples. Therefore, estimation of 
total protein in timely collected urine samples is the 
method of choice. Assessing protein and creatinine on 
near-24-hour urine samples can offset error in urine 
collection.
Normoglycemic glycosuria is another element that 
suggests the presence of proximal tubular damage. 
Moreover, since uric acid is highly reabsorbed at this 
nephron level, with a fractional excretion that usually 
does not exceed 10% of the filtered uric acid, an in-
crease in urinary uric acid excretion is an early marker 
of proximal tubular dysfunction.
Microalbuminuria
Chronic kidney disease and overt proteinuria have 
been associated with adverse outcomes in HIV-infected 
patients130,131. Lower levels of urinary albumin excretion, 
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or microalbuminuria, have also been associated with 
increased mortality in diabetics132. Several studies have 
demonstrated an increased prevalence of microalbu-
minuria in HIV-infected individuals both before133 and 
after the introduction of HAART26,27. A recent study 
identiﬁed a graded relationship between the degree of 
microalbuminuria and the risk of mortality134. The de-
tection of proteinuria or microalbuminuria on a single 
urine specimen was associated with an increased risk 
of mortality, even after adjustment for markers of HIV 
disease severity. The data suggest that microalbuminuria 
testing may prove useful as prognostic information in 
HIV-infected individuals.
Beta 2 microglobinuria
Beta 2 microglobinuria (B2M) is a specific marker of 
tubular damage.
In a paper by Soriano, et al., urinary B2M excretion 
was particularly high in a group of HIV-infected patients 
receiving tenofovir-including HAART, but it turned out 
to be elevated, even if at lower levels when compared 
to the above group, also in HIV-infected patients with 
a detectable viremia as to suggest a role in the tubular 
damage of HIV itself. Beta 2 microglobinuria was within 
a normal range in patients with suppressed viremia not 
receiving tenofovir-including HAART99.
In a small case series, increased urinary excretion of 
B2M was reported after 12 weeks in a group of tenofovir-
treated patients in comparison with other antiretroviral-
treated patients. Interestingly, the fractional reabsorp-
tion of phosphate decreased progressively from 12 to 
24 weeks, suggesting that B2M excretion could be 
interpreted as an early marker of tubular dysfunction, 
manifested later on with an increased urinary loss of 
phosphate135.
In larger studies, urinary B2M levels were elevated 
in a higher proportion of tenofovir-treated patients com-
pared with non-tenofovir-treated patients. Serum crea-
tinine and creatinine clearance or eGFR did not differ 
significantly in the two groups136.
Measurement of urinary B2M, however, presents 
some troubles due to the easy degradation of the mole-
cule at low pH; therefore, this marker has lost its utility 
in the evaluation of tubular dysfunction in general.
N-acetyl-beta-D-glucosaminidase
N-acetyl-beta-D-glucosaminidase (NAG) is a lyso-
somal enzyme contained in the proximal tubular cells 
and has been used as a marker of cell damage and 
tubular dysfunction. NAG enzymuria is increased in 
both tenofovir-containing HAART and non-tenofovir 
HAART compared to naive patients98.
Retinol binding protein
Retinol binding protein (RBP) is low molecular weight 
protein completely filtered by the glomerulus and 
reabsorbed by the proximal tubule. Its presence in 
urine is an indirect index of tubular damage. High 
values of urinary excretion of RBP have been found in 
patients treated with tenofovir-containing HAART98,101.
Novel markers
Neutrophil gelatin-associated lipocalin
Neutrophil gelatin-associated lipocalin (NGAL) is 
supposed to be an early and sensitive marker of acute 
renal damage128. Although this marker has been stud-
ied extensively in different clinical settings, such as 
sepsis, cardiopulmonary bypass, multiple organ failure, 
renal drug toxicity, and acute rejection, in HIV-infected 
patients, NGAL has been only studied in pediatric pa-
tients. This study showed a progressive reduction of 
NGAL in children with demonstrated HIVAN at the renal 
biopsy compared to the beginning of HAART137. How-
ever, it is not clear if such decrease is due to the im-
provement of the cellular immunity related to HAART 
or just to the recovery of kidney function.
Asymmetric dimethylarginine
Asymmetric dimethylarginine (ADMA) is an inhibitor 
of nitric oxide synthetase and reflects the endothelial 
function. In HIV-negative patients with kidney disease, 
this marker has been associated to a faster progression 
to dialysis138.
Liver-type fatty acid binding protein
Liver-type fatty acid binding protein (L-FABP) is a 
marker of integrity of the proximal tubule. In a study on 
120 patients with CKD, without diabetes and without 
HIV infection, this marker has not turned out to be related 
to elevated levels of proteinuria and creatininemia139.
In the literature, no studies have analyzed the role of 
these markers in HIV-infected patients, particularly the 
last two ones.
Accordingly with what so far discussed, we propose 
a practical algorithm that nicely fits with our clinical 
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Figure 2. A practical approach to kidney disease in HIV-1 patients.
Qualitative assessment for risk of kidney disease
– Race
– Family history of kidney disease
– CD4+ lymphocyte count*
– HIV RNA level*
– History of use of nephrotoxic drugs
– Comorbidities*
  •  Diabetes mellitus
  •  Hypertension
  •  Hepatitis coinfection
Screening at diagnosis
– Proteinuria
 [dipstick in morning urine sample] abnormal values ≥ 1+
– Hematuria
 [dipstick in morning urine sample]
– Serum creatinine 
 [estimate creatinine clearance or eGFR calculation with appropriate formula†]
– Serum Phosphate abnormal value < 2.5 mg/dl
Abnormal values
– Proteinuria
  Evaluation of spot urine protein/creatinine ratio 
[uP/uCr] or 24h urine. If confirmed refer to 
nephrologist for evaluation
– Hematuria
 refer to nephrologist for evaluation
– eGFR < 69 ml/min/1.73 m2
 monitor every 3-4 months
– eGFR < 60 ml/min/1.73 m2
 refer to nephrologist for evaluation 
– eGFR declining over time
  refer to a nephrologist for evaluation
– Serum phosphate < 2.5 mg/dl
 refer to nephrologist for evaluation
If eGFR < 80 ml/min/1.73m² adjust drug dosage, 
accordingly with table 2
Normal values
–  Monitor annually in ART-naive patients
–  Repeat before starting ART, after 4 
weeks and monitor annually 
–  If TDF-based ART: after 2, 4 and 12 
weeks, then monitor every 6 months
*Periodical reevaluation
†Use Cockroft-Gault or MDRD; use CKD-EPI only if creatininemia is estimated with Roche enzymatic IDMS
MDRD: Modification of Diet in Renal Disease; CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration; eGFR: estimated glomerular filtration rate;  
ART: antiretroviral therapy; TDF: tenofovir.
experience in the management of kidney disease during 
HIV infection (Fig. 2).
The future of the renal damage
With the advent of HAART, physicians facing HIV 
infection have been forced to switch their attention 
from the control of viral load and immunological state 
toward a deeper comprehension and management of 
comorbidities140. In fact, HIV and HAART can harm many 
organs and tissues and undoubtedly kidneys are main 
targets. The onset of HIVAN is well described, but, 
fortunately, it is also quite rare24. Many other alterations 
of renal function have been growing during the years.
As discussed in other sections of this review, the 
counterpart of the reduction of AIDS-related deaths 
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has been the increased mortality for renal and cardio-
vascular diseases, and this has defined, also in HIV-
positive populations, a close correlation between kid-
neys and heart141. Many data confirm that a reduction 
of GFR is strictly correlated with increased CVD, both 
in the general population and in HIV-positive subjects. 
In addition to traditional risk factors known to reduce 
GFR (such as aging, race, diabetes, hypertension), 
many infection-related conditions can exacerbate car-
diovascular risk: use of tenofovir and PI, coinfection 
with HBV, opportunistic infections, low CD4+ nadir, 
high plasma HIV-RNA53,62,93,142-146.
Alterations in GFR can also cause bone derange-
ment. Dialysis patients frequently show a bone disease 
called renal osteodystrophy, but also slighter reduc-
tions of GFR can negatively affect bone health, by in-
creasing parathyroid hormone production and osteo-
clast activity and by reducing the activation of vitamin 
D147. A growing body of evidence demonstrates that 
these alterations of mineral metabolism can increase 
CVD148,149. In patients with osteoporotic fractures, the 
hazard ratios for stroke and first cardiovascular event 
are 4.1 and 4.7, respectively148.
All these considerations seem to close the circle. 
Kidneys, heart, and bone share common risk factors 
that can damage all these organs and tissues. Due 
to its central role, GFR could be regarded as one of 
the trait d’union between these apparently different 
diseases.
Patient’s perspective
Renal complications are common among people 
living with HIV: in fact, up to 30%12 of HIV-positive 
individuals may have protein in their urine, a sign of 
kidney dysfunction. It is difficult to estimate accu-
rately how many people develop kidney disease and, 
therefore, to implement effective disease prevention 
or early intervention because kidney dysfunction may 
be asymptomatic or may result in only vague symptoms 
such as fatigue or general malaise. Without specific 
symptoms, many individuals are diagnosed later in 
their disease course, reducing the efficacy of available 
treatments.
Given the risks associated with kidney disease, de-
veloping awareness of kidney function and getting the 
necessary tests are essential to maintaining good 
health with HIV.
Our knowledge that HIV affects the kidneys is solid, 
but our understanding of certain areas of renal health 
is still rudimentary. Significant work remains to truly 
elucidate who is susceptible to kidney disease and 
why, and how to treat certain kidney diseases that oc-
cur in HIV-positive people.
Early screening for kidney disease provides a great-
er likelihood of effective prevention and treatment. 
Screening and risk assessment are as simple as a 
urine analysis for protein, blood test for serum creatinine, 
and simple formulas for specific evaluations. They 
should be performed in every person living with HIV: 
the Italian Guidelines on the HIV-1 therapy and man-
agement of people living with HIV/AIDS currently 
strongly recommends that all HIV-positive people 
should be screened for kidney disease at least once a 
year, and those with abnormal screening tests should 
receive further evaluation by their HIV physician and 
see, when necessary, a nephrologist.
Key to this recommendation is awareness of kidney 
disease. Without awareness in both the HIV-positive 
community and among HIV physicians, potentially 
preventable and treatable problems can progress 
unchecked in the unsuspecting and asymptomatic 
individual. Awareness can lead to a very simple, but 
potentially life-saving, question: “Hey doc, are my 
kidneys OK?”
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